GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.
暂无分享,去创建一个
Wei Wu | Fan Wu | Jing Gao | Xiangqian Su | Lin Shen | Zaozao Wang | Wei Wu | Zaozao Wang | L. Shen | Jing Gao | Fan Wu | Lei Chen | Beihai Jiang | J. Di | Jiayuan Wang | Kai Xu | Jiabo Di | Aidong Wang | B. Jiang | Lei Chen | X. Su | Kai Xu | Aidong Wang | Jiayuan Wang
[1] Xianzhu Yang,et al. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma. , 2014, Molecular pharmaceutics.
[2] Sabine Tejpar,et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. , 2011, The Lancet. Oncology.
[3] Rebecca L. Siegel Mph,et al. Colorectal cancer statistics, 2014 , 2014 .
[4] Y. Toiyama,et al. The prognostic value of KRAS mutations in patients with colorectal cancer. , 2012, Oncology reports.
[5] Kate Johnson,et al. Advances in the management of colorectal cancer: from biology to treatment , 2014, International Journal of Colorectal Disease.
[6] F.A.M. Bordonaba,et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .
[7] G. Neale,et al. Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice. , 2015, Experimental hematology.
[8] A. Jemal,et al. Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[9] V. Bigley,et al. Haematopoietic and immune defects associated with GATA2 mutation , 2015, British journal of haematology.
[10] Ben Readhead,et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. , 2015, Cancer cell.
[11] Jung Eun Lee,et al. Sex- and gender-specific disparities in colorectal cancer risk. , 2015, World journal of gastroenterology.
[12] P. Delrio,et al. Genetics, diagnosis and management of colorectal cancer (Review) , 2015, Oncology reports.
[13] S. Holland,et al. GATA2 deficiency , 2015, Current opinion in allergy and clinical immunology.
[14] A. Cerone,et al. Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. , 2016, Journal of theoretical biology.
[15] Masayuki Yamamoto,et al. GATA2 is critical for the maintenance of cellular identity in differentiated mast cells derived from mouse bone marrow. , 2015, Blood.
[16] C. Shou,et al. Prognostic value of PRL‐3 overexpression in early stages of colonic cancer , 2009, Histopathology.
[17] S. Qiu,et al. Decreased Expression of GATA2 Promoted Proliferation, Migration and Invasion of HepG2 In Vitro and Correlated with Poor Prognosis of Hepatocellular Carcinoma , 2014, PloS one.
[18] Julian Downward,et al. The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer , 2012, Cell.
[19] K. Matsuo,et al. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. , 2015, World journal of gastroenterology.
[20] M. Odero,et al. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. , 2012, Critical reviews in oncology/hematology.
[21] Supriya Patel,et al. Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer , 2012, International journal of molecular sciences.
[22] D. Carraro,et al. Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports , 2011, International Journal of Colorectal Disease.
[23] N. Zhang,et al. Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer , 2013, Medical Oncology.
[24] A. Jemal,et al. Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[25] A. Jemal,et al. Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[26] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[27] S. Orkin,et al. Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. , 1997, Blood.
[28] J. Darnell. Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.
[29] K. Nephew,et al. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer , 2014, Nucleic acids research.
[30] C. Eng,et al. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. , 2012, Human molecular genetics.
[31] D. Berger,et al. GATA Factors in Gastrointestinal Malignancy , 2011, World Journal of Surgery.
[32] L. Shen,et al. Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. , 2010, World journal of gastroenterology.
[33] Arnulf Stenzl,et al. Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma , 2015, Targeted Oncology.
[34] S. Leng,et al. GATA2 is Epigenetically Repressed in Human and Mouse Lung Tumors and Is Not Requisite for Survival of KRAS Mutant Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[35] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.